HBM Holdings to collaborate with AstraZeneca and sell shares

HBM Holdings announced a strategic collaboration with AstraZeneca to discover and develop next-generation multi-specific antibodies, where AstraZeneca secures the option to license two preclinical immunology programs and nominate a target for HBM Shanghai, receiving options for additional programs. In return, HBM Shanghai will receive $175 million in upfront and milestone payments, plus up to $4.4 billion in development and commercial milestones, and tiered royalties.